聊天GPT与神经心理学数据的舞蹈:阿尔茨海默病病的案例研究
Mohamad El Haj1, Claire Boutoleau-Bretonnière2, Guillaume Chapelet3
1Institut Universitaire de France, Paris, France; CHU Nantes, Clinical Gerontology Department, Bd Jacques Monod, F44093 Nantes, France.
Ageing research reviews
|November 5, 2023
概括
聊天GPT可以解释神经心理测试成绩,但与标准化成绩和识别特定认知领域的斗争. 神经心理学家擅长识别模式,以诊断诸如阿尔茨海默病等疾病.
科学领域:
- 神经学 神经学
- 人工智能的人工智能
- 认知科学 认知科学
背景情况:
- 人工智能 (AI),特别是像ChatGPT这样的大型语言模型,正在越来越多地影响科学和医学领域.
- 人工智能在解释复杂的医疗数据,如神经心理查等方面的应用需要仔细评估.
- 阿尔茨海默病的诊断严重依赖于精确的神经心理评估.
研究的目的:
- 评估ChatGPT在解释神经心理查数据中的准确性.
- 为了将ChatGPT的解释与经验丰富的神经心理学家对轻度阿尔茨海默病患者的解释进行比较.
- 确定AI在认知障碍评估中的优点和局限性.
主要方法:
- 聊天GPT提供了来自诊断为轻度阿尔茨海默病的患者的匿名神经心理测试数据.
- 人工智能的解释与两位临床神经心理学家的解释进行了比较.
- 分析的重点是分数解释,使用标准化分数和认知领域的识别.
主要成果:
- 聊天GPT准确地解释了个人的神经心理测试成绩.
- 然而,ChatGPT并没有使用标准化得分或指定受影响最大的认知领域.
- 神经心理学家使用标准化得分来确定记忆力下降是主要障碍.
结论:
- 虽然像ChatGPT这样的AI可以提供对神经心理测试结果的一般见解,但目前它缺乏人类专家的细微模式识别能力.
- 对于像阿尔茨海默氏症这样的疾病,专家临床医生对于详细的诊断和确定认知缺陷的性质至关重要.
- 人工智能需要进一步发展,才能有效地整合标准化得分,并在临床实践中识别特定的认知领域障碍.
更多相关视频
08:43Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
Published on: August 7, 2017
7.9K
06:46Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage
Published on: August 4, 2018
12.2K
相关概念视频
Alzheimer's Disease: Overview
498
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
498
Alzheimer's Disease: Treatment
197
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
197
